AMAG Pharmaceuticals, Inc.’s (AMAG) share price has entered into oversold territory with an RSI value of 28.86. The Zacks Consensus Estimate on AMAG Pharmaceuticals, Inc.’s earnings for the full year period has loss by 0.02 cents over the past two months to $0.51 per share. Currently, AMAG Pharmaceuticals, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (AMAG) after its recent drop.
AMAG PHARMACEUTICALS INC (AMAG): Free Stock Analysis Report
Zacks Investment Research
- Utility Industry